Navigation Links
New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study
Date:10/2/2007

BRANFORD, Conn., Oct. 2 /PRNewswire/ -- 454 Life Sciences, a Roche company, and Perlegen Sciences, Inc., today announced a collaboration to conduct large scale genetic re-sequencing in hundreds of DNA samples collected by Perlegen from humans with specific responses to a widely prescribed class of drug. The goal of the collaboration will be to determine whether sufficient genetic variation can be identified and validated to create a clinical test that will predict how people might respond to this class of medicines.

Pursuant to the terms of the agreement, Perlegen and 454 will each re- sequence select portions of the genome within each sample, using 454 Sequencing(TM) technology and DNA amplified with Perlegen's proprietary sample preparation and amplification technologies. The parties' data analysis teams will jointly study the combined results to determine how significant a role variation in genetic sequence plays in patient response to this drug class.

"We are pleased to be working with 454 in this landmark pharmacogenomic study that combines 454's exceptional next generation sequencing technology with Perlegen's expertise in defining genetic variation on a carefully selected sample set," commented Bryan Walser, MD, Chief Executive Officer of Perlegen Sciences. "This study holds the promise to improve therapeutic outcomes for a vast number of patients."

"454 Sequencing, with long, highly-accurate reads, is ideally suited for a project of this scale and importance," commented Christopher McLeod, President and CEO of 454. "We look forward to partnering with Perlegen in the quest to solve this and other critically important medical problems."

454 Life Sciences develops and commercializes the innovative Genome Sequencer(TM) system for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of whole genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of 454 Sequencing(TM) are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired reads. 454 Sequencing technology has enabled many peer-reviewed studies in diverse research fields such as: cancer research, infectious diseases research, drug discovery, marine biology, anthropology, paleontology, and many more.

For additional information, please visit http://www.454.com.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our website at http://www.roche.com.

About Perlegen Sciences

Perlegen's mission is to discover and commercialize genetic variations that can make a difference to patients and physicians. The company's expertise is in understanding human genetic variation within and across diverse patient populations and in conducting studies aimed at identifying those variations that are predictive of drug response, both toxicity and efficacy. For more information about the company and its technologies, visit Perlegen's website at http://www.perlegen.com.

For more information, please contact

Roche Diagnostics GmbH

Dr. Burkhard Ziebolz

Phone +49 (8856) 60 4830

Email: burkhard.ziebolz@roche.com

Russo Partners, LLC

Tony Russo

(212) 845-4251

Tony.russo@russopartnersllc.com

Russo Partners, LLC

Benjamin Carmichael

(212) 845-4242

Benjamin.carmichael@russopartnersllc.com


'/>"/>
SOURCE 454 Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
2. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
3. Perscitus Biosciences secures $250K Commerce loan
4. Wisconsin biosciences rise to the challenge
5. Wisconsin professors elected to National Academy of Sciences
6. Quintessence Biosciences advances cancer drug
7. Quintessence Biosciences names new president
8. InvivoSciences receives NIH grant for heart technology
9. Caden Biosciences may signal critical mass
10. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
11. QBI Life Sciences snags $130,000 NIH grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):